Mirpresoc (Telmisartan)

Telmisartan is used to manage conditions related to the renin‑angiotensin‑aldosterone system.

• Hypertension: lowers systolic and diastolic blood pressure, helping to prevent stroke, myocardial infarction, and other complications.
• Cardiovascular risk reduction: reduces the likelihood of major adverse cardiovascular events such as heart attack, stroke, and cardiovascular death in patients with established risk factors.
• Diabetic nephropathy: slows the decline of renal function and reduces albuminuria in patients with type 2 diabetes and hypertension.

• Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction, aldosterone secretion, and sympathetic activation. By inhibiting this pathway, it promotes vasodilation, reduces sodium and water retention, and lowers peripheral vascular resistance, leading to a sustained decrease in blood pressure. The blockade also improves endothelial function and attenuates inflammatory processes associated with hypertension, contributing to long‑term cardiovascular protection.

Telmisartan may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: light‑headedness, especially after initial dosing.
• Headache: mild to moderate intensity.
• Diarrhea: loose stools or increased frequency.

Serious or Rare Side Effects

• Hyperkalemia: high potassium levels that can affect heart rhythm.
• Renal impairment: rise in serum creatinine indicating reduced kidney function.
• Angioedema: swelling of the face, lips, tongue, or airway.

When prescribing Telmisartan, clinicians should consider several precautionary measures to ensure safe use.

• Pregnancy: contraindicated in pregnancy (Category D) due to risk of fetal toxicity.
• Renal function: monitor kidney function; dose adjustment may be needed in severe impairment.
• Electrolytes: check serum potassium before initiating therapy and periodically thereafter.
• Concomitant ARBs/ACE inhibitors: avoid combined use to reduce risk of hyperkalemia and renal failure.
• Hepatic impairment: use with caution in patients with liver disease.
• Store at ambient temperature: keep below 25 °C, protect from moisture, and retain in original packaging.

Telmisartan can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• ACE inhibitors: concurrent use may increase risk of hyperkalemia and renal dysfunction.
• Potassium‑sparing diuretics or supplements: can cause dangerous hyperkalemia.
• Aliskiren (in diabetics): combined use raises risk of renal impairment, hypotension, and hyperkalemia.

Moderate Interactions (Monitor Closely)

• NSAIDs: may reduce antihypertensive effect and impair renal function.
• Diuretics (thiazides): may enhance hypotensive response; monitor blood pressure.
• Lithium: increased lithium levels; monitor for toxicity.
• CYP2C9 inhibitors (e.g., fluconazole): may raise telmisartan plasma concentrations.